Business Context and Reporting Period
Company: Allogene Therapeutics, Inc. (ALLO)
Filing Type: Form 8-K (Current Report)
Date: April 13, 2026
Subject: Announcement of interim futility analysis results from the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) for first-line consolidation in large B-cell lymphoma (LBCL).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial data and does not contain financial statements. The document does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The report details interim data from the first 24 randomized patients (12 in the cema-cel arm, 12 in the observation arm) of the ALPHA3 trial.
Efficacy Results
- MRD Negativity: 58.3% (7/12) of patients in the cema-cel arm achieved Minimal Residual Disease (MRD) negativity compared to 16.7% (2/12) in the observation arm, representing a 41.6% absolute difference.
- ctDNA Reduction: At Day 45, plasma ctDNA levels decreased by a median of 97.7% in the cema-cel arm versus a 26.6% median increase in the observation arm.
- Primary Endpoints: Event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) remain blinded.
Safety and Tolerability
- Adverse Events: No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD) were reported in the cema-cel arm.
- Neurologic Events: 50.0% (6/12) of cema-cel patients experienced low-grade neurologic events (e.g., headache, dizziness); no Grade 3 or higher events occurred.
- Infections: 16.7% (2/12) of cema-cel patients experienced low-grade infections; no Grade 3 or higher infections occurred.
- Hospitalization: 10 of 12 cema-cel patients were managed entirely as outpatients. Two required brief hospitalization for events deemed unrelated to treatment.
Patient Demographics
The cema-cel arm included patients with numerically more aggressive disease features, including 100% Stage III-IV disease and a higher proportion of Double Hit gene alterations (50.0%) compared to the observation arm.
Guidance, Outlook, and Risks
Future Milestones
- Enrollment: The trial is enrolling across 60+ sites with a target of approximately 220 patients, expected to be complete by the end of 2027.
- Data Readouts: Interim EFS analysis is anticipated in mid-2027; primary EFS analysis is expected in mid-2028.
- Regulatory Path: Positive results could support a Biologics License Application (BLA) submission.
Risks and Contingencies
- Clinical Uncertainty: Interim data from a small sample size may not be predictive of final results.
- MRD Significance: Uncertainty exists regarding whether MRD clearance improvements translate to meaningful clinical benefits (EFS/OS).
- Financial Needs: The company notes a need for additional capital as a risk factor.
- Forward-Looking Statements: Actual results may differ materially due to risks inherent in clinical development, manufacturing, and regulatory approvals.
Investor Verification Checklist
- Verify the correlation between the observed 41.6% MRD clearance difference and long-term Event-Free Survival (EFS) in the full study population.
- Monitor the safety profile as the trial expands to 220 patients, specifically regarding the absence of CRS and ICANS in the larger cohort.
- Confirm the timeline for the mid-2027 interim EFS analysis and the company's capital position to fund operations through 2028.
- Review the reliability of the Natera CLARITY MRD assay as a surrogate endpoint for clinical benefit.